Mayne Pharma Group (ASX:MYX) said it provided Cosette Pharmaceuticals with a notice of termination of the scheme implementation deed (SID) for the proposed acquisition of the company by Cosette because the scheme was not implemented, according to a Thursday filing with the Australian bourse.

The termination releases Mayne from the restrictions imposed on it under the terms of the scheme and does not give rise to any obligation for the company to pay the break fee, the filing said.

The company said it plans to enforce the costs order made against Cosette in October.